Article

A molecular and clinical study of Larsen syndrome caused by mutations in FLNB

Department of Paediatrics and Child Health, University of Otago, Dunedin, New Zealand.
Journal of Medical Genetics (Impact Factor: 5.64). 03/2007; 44(2):89-98. DOI: 10.1136/jmg.2006.043687
Source: PubMed

ABSTRACT Larsen syndrome is an autosomal dominant osteochondrodysplasia characterised by large-joint dislocations and craniofacial anomalies. Recently, Larsen syndrome was shown to be caused by missense mutations or small inframe deletions in FLNB, encoding the cytoskeletal protein filamin B. To further delineate the molecular causes of Larsen syndrome, 20 probands with Larsen syndrome together with their affected relatives were evaluated for mutations in FLNB and their phenotypes studied.
Probands were screened for mutations in FLNB using a combination of denaturing high-performance liquid chromatography, direct sequencing and restriction endonuclease digestion. Clinical and radiographical features of the patients were evaluated.
The clinical signs most frequently associated with a FLNB mutation are the presence of supernumerary carpal and tarsal bones and short, broad, spatulate distal phalanges, particularly of the thumb. All individuals with Larsen syndrome-associated FLNB mutations are heterozygous for either missense or small inframe deletions. Three mutations are recurrent, with one mutation, 5071G-->A, observed in 6 of 20 subjects. The distribution of mutations within the FLNB gene is non-random, with clusters of mutations leading to substitutions in the actin-binding domain and filamin repeats 13-17 being the most common cause of Larsen syndrome. These findings collectively define autosomal dominant Larsen syndrome and demonstrate clustering of causative mutations in FLNB.

Download full-text

Full-text

Available from: Louise S Bicknell, Aug 13, 2015
0 Followers
 · 
184 Views
  • Source
    • "The clinical and radiographic phenotypes were reviewed by one of us (SR) to ensure the diagnoses were correctly assigned according to previously published criteria [Bicknell et al., 2007; Farrington-Rock et al., 2006]. The exon and intron– exon boundaries of FLNB were amplified by polymerase chain reaction (PCR) using previously published primers [Krakow et al., 2004] and subjected to denaturing high performance liquid chromatography (DHPLC) using the WAVE platform (Transgenomic, Omaha, NE) or using direct sequencing on an ABI3100 capillary sequencer as previously described [Bicknell et al., 2007]. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence NM_001457.3. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dominant missense mutations in FLNB, encoding the actin-cross linking protein filamin B (FLNB), cause a broad range of skeletal dysplasias with varying severity by an unknown mechanism. Here these FLNB mutations are shown to cluster in exons encoding the actin-binding domain (ABD) and filamin repeats surrounding the flexible hinge 1 region of the FLNB rod domain. Despite being positioned in domains that bind actin, it is unknown if these mutations perturb cytoskeletal structure. Expression of several full-length FLNB constructs containing ABD mutations resulted in the appearance of actin-containing cytoplasmic focal accumulations of the substituted protein to a degree that was correlated with the severity of the associated phenotypes. In contrast, study of mutations leading to substitutions in the FLNB rod domain that result in the same phenotypes as ABD mutations demonstrated that with only one exception disease-associated substitutions, surrounding hinge 1 demonstrated no tendency to form actin-filamin foci. The exception, a substitution in filamin repeat 6, lies within a region previously implicated in filamin-actin binding. These data are consistent with mutations in the ABD conferring enhanced actin-binding activity but suggest that substitutions affecting repeats near the flexible hinge region of FLNB precipitate the same phenotypes through a different mechanism.
    Human Mutation 04/2012; 33(4):665-73. DOI:10.1002/humu.22012 · 5.05 Impact Factor
  • Source
    • "Moreover, they interact directly with a plethora of cellular proteins of great functional diversity, indicating that they are multifunctional signalling adapter proteins (Stossel et al., 2001; van der Flier et al., 2002 Feng and Walsh, 2004; Popowicz et al., 2006;). The human filamin family consists of three isoforms, filamins A, B and C. Mutations in filamin A and B have been reported to cause a broad range of congenital malformations, affecting brain, bone and other organs (Robertson et al., 2003; Bicknell et al., 2007). Filamin C (formerly also called filamin 2, g-filamin or ABP-L) is the muscle-specific filamin isoform. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in the filamin C gene (FLNC) cause a myofibrillar myopathy (MFM), morphologically characterized by focal myofibrillar destruction and abnormal accumulation of several proteins within skeletal muscle fibres. We studied 31 patients from four German families to evaluate the phenotype of filaminopathy. All patients harboured the same p.W2710X mutation in FLNC. Haplotype analysis suggested a founder mutation in these German filaminopathy families. The mean age at onset of clinical symptoms was 44 +/- 6 years (range, 24-57 years). Slowly progressive muscle weakness was mostly pronounced proximally, initially affecting the lower extremities and involving the upper extremities in the course of disease progression, similar to the distribution of weakness seen in limb-girdle muscular dystrophies (LGMD). Patients frequently developed respiratory muscle weakness. About one-third of the patients showed cardiac abnormalities comprising conduction blocks, tachycardia, diastolic dysfunction and left ventricular hypertrophy indicating a cardiac involvement in filaminopathy. Serum creatine kinase levels varied from normal up to 10-fold of the upper limit. Magnetic resonance imaging studies showed a rather homogenous pattern of muscle involvement in the lower extremities differing from that in other types of MFM. Myopathological features included perturbation of myofibrillar alignment, accumulation of granulofilamentous material similar to that seen in primary desminopathies and abnormal intracellular protein deposits typical of MFM. Decreased activities of oxidative enzymes and fibre hypertrophy seem to be early features, whereas dystrophic changes were present in advanced stages of filaminopathy. Rimmed vacuoles were detected in only a few cases. The intracellular aggregates were composed of a variety of proteins including filamin C, desmin, myotilin, Xin, dystrophin and sarcoglycans. Therapy is so far limited to symptomatic treatment. The German filaminopathy cohort, the largest group of patients studied so far, shares phenotypic features with LGMD and presents with characteristic histopathological findings of MFM.
    Brain 01/2008; 130(Pt 12):3250-64. DOI:10.1093/brain/awm271 · 10.23 Impact Factor
  • Article: Case Report
    [Show abstract] [Hide abstract]
    ABSTRACT: We treated a patient with multiple congenital joint dislocations and facial dysmorphisms consistent with Larsen syndrome. Sequencing of the FLNB gene resulted in identification of a novel, de novo 508G>C point mutation resulting in substitution of proline for a highly conserved alanine (A170P). This mutation has not been described previously but is likely causative because this alanine is highly conserved and is located in the calponin homology domain where other mutations have been described. We also report the successful use of a minimally invasive technique in achieving initial correction of bilateral congenital knee dislocations in this patient. The technique consists of serial manipulations and castings followed by an open quadriceps tenotomy. Longer followup is needed to ensure maintenance of correction and to avoid the need for more extensive surgery, which has been the traditional treatment for congenital knee dislocation associated with Larsen syndrome.
    Clinical Orthopaedics and Related Research 06/2008; 466(6):1503-1509. DOI:10.1007/s11999-008-0196-5 · 2.88 Impact Factor
Show more